Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-Imidazolide

Centers for Disease Control and Prevention (http://www.cdc.gov/nccdphp/dnpa/obesity/index.htm).

Cerulli, 2007, Update on the pharmacotherapy of obesity, Ann. Pharmacother., 41, 1505, 10.1345/aph.140066

Dinkova-Kostova, 2005, Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress, Proc. Natl. Acad. Sci. U. S. A., 102, 4584, 10.1073/pnas.0500815102

Ginter, 2008, Adult obesity at the beginning of the 21st century: epidemiology, pathophysiology and health risk, Bratisl. Lek. Listy, 109, 224

Hughes, 2008, The synthetic triterpenoid CDDO-Im inhibits fatty acid synthase expression and has antiproliferative and proapoptotic effects in human liposarcoma cells, Cancer Invest., 26, 118, 10.1080/07357900701522612

Iida, 2004, Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis, Cancer Res., 64, 6424, 10.1158/0008-5472.CAN-04-1906

Kensler, 2007, Cell survival responses to environmental stresses via the Keap1–Nrf2–ARE pathway, Annu. Rev. Pharmacol. Toxicol., 47, 89, 10.1146/annurev.pharmtox.46.120604.141046

Lusk, 1928

Pfaffl, 2001, A new mathematical model for relative quantification in real-time RT-PCR, Nucleic Acids Res., 29, e45, 10.1093/nar/29.9.e45

Pope, 1987, Effects of glucocorticoid and thyroid hormones on regulatory enzymes of fatty acid synthesis and glycogen metabolism in developing fetal rat lung, Biochim. Biophys. Acta, 918, 141, 10.1016/0005-2760(87)90189-5

Qureshi, 2007, Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver, World J. Gastroenterol., 13, 3540, 10.3748/wjg.v13.i26.3540

Rosen, 2005, The transcriptional basis of adipocyte development, Prostaglandins Leukot. Essent. Fatty Acids, 73, 31, 10.1016/j.plefa.2005.04.004

Rosen, 2006, Adipocyte differentiation from the inside out, Nat. Rev., Mol. Cell. Biol., 7, 885, 10.1038/nrm2066

Shin, 2007, NRF2 modulates aryl hydrocarbon receptor signaling: influence on adipogenesis, Mol. Cell. Biol., 27, 7188, 10.1128/MCB.00915-07

Sussan, 2009, Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice, Proc. Natl. Acad. Sci. U. S. A., 106, 250, 10.1073/pnas.0804333106

Tanaka, 2008, NF-E2-related factor 2 inhibits lipid accumulation and oxidative stress in mice fed a high-fat diet, J. Pharmacol. Exp. Ther., 325, 655, 10.1124/jpet.107.135822

Toye, 2007, Subtle metabolic and liver gene transcriptional changes underlie diet-induced fatty liver susceptibility in insulin-resistant mice, Diabetologia, 50, 1867, 10.1007/s00125-007-0738-5

Weigle, 2003, Pharmacological therapy of obesity: past, present, and future, J. Clin. Endocrinol. Metab., 88, 2462, 10.1210/jc.2003-030151

Winzell, 2004, The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes, Diabetes, 53, S215, 10.2337/diabetes.53.suppl_3.S215

Wolfgang, 2006, The role of hypothalamic malonyl-CoA in energy homeostasis, J. Biol. Chem., 281, 37265, 10.1074/jbc.R600016200

Yang, 2001, Decreased lipid synthesis in livers of mice with disrupted Site-1 protease gene, Proc. Natl. Acad. Sci. U. S. A., 98, 13607, 10.1073/pnas.201524598

Yates, 2006, Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-, 12-dioxooleana-1, 9(11)-dien-28-oyl]imidazole, Cancer Res., 66, 2488, 10.1158/0008-5472.CAN-05-3823

Yates, 2007, Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes, Mol. Cancer Ther., 6, 154, 10.1158/1535-7163.MCT-06-0516

Yates, 2009, Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice, Carcinogenesis, 30, 1024, 10.1093/carcin/bgp100